iBio (IBIO) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iBio (IBIO) has outperformed Mereo BioPharma Group (MREO) over the past year, gaining 5.7% versus a loss of 80.9%. Over five years, MREO leads with a -82.8% price change compared with -99.8% for IBIO. iBio is the larger company by market cap ($56.0 million vs $55.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBIO | MREO |
|---|---|---|
| Share price | $0.871 | $0.3499 |
| Market cap | $56.01M | $55.88M |
| 1-day change | -5.33% | -6.74% |
| YTD return | -52.33% | -10.02% |
| 1-year return | +5.75% | -80.86% |
| 5-year return | -99.80% | -82.79% |
| EPS (TTM) | $-0.32 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $2.37 |
| 52-week low | $0.78 | $0.20 |
| Distance from 52-week high | -77.20% | -85.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +553.27% | +460.16% |
| Average volume | 727.93K | 4.04M |
| Shares outstanding | 64.31M | 159.69M |
| Employees | 23 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed MREO by 86.6 percentage points over the past year.
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
IBIO vs MREO FAQ
Which is bigger, iBio or Mereo BioPharma Group?
iBio (IBIO) is larger, with a market capitalization of $56.01M compared with $55.88M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, IBIO or MREO?
IBIO returned +5.75% over the past 12 months, compared with -80.86% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are iBio and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.